Adamis Pharmaceuticals Corp (ADMP): David J. Marguglio , SR VP of Corporate Development of Adamis Pharmaceuticals Corp sold 4,860 shares on May 9, 2016. The Insider selling transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were sold at $10.00 per share for a total value of $48,600.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 6, 2016, David J. Marguglio (SR VP of Corporate Development) sold 4,860 shares at $9.17 per share price.On Aug 17, 2015, Richard C Williams (director) purchased 9,800 shares at $3.26 per share price.Also, On Aug 17, 2015, Robert B Rothermel (director) purchased 7,000 shares at $3.35 per share price.
Shares of Adamis Pharmaceuticals Corp (ADMP) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -1.13 points or -11.17% at $8.99 with 6,29,262 shares getting traded. Post opening the session at $10.76, the shares hit an intraday low of $8.98 and an intraday high of $10.98 and the price vacillated in this range throughout the day. The company has a market cap of $121 M and the number of outstanding shares has been calculated to be 1,34,59,061 shares. The 52-week high of Adamis Pharmaceuticals Corp is $10.98 and the 52-week low is $3.05.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is developing various products in the allergy and respiratory markets The Company’s product portfolio includes specialty pharmaceutical products such as Epinephrine pre-filled syringe (PFS) APC-5000 dry powder inhaler (DPI) APC-1000 APC-2000 and APC-3000 and biotechnology products such as TeloB-VAX (vaccine) APC-100 APC-200 and APC-300. The Company’s product candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are APC-5000 DPI and APC-1000. The Company’s other product candidates in its allergy and respiratory product pipeline include APC-1000 APC-3000 and APC-2000. The Company’s drug candidates for the treatment of prostate cancer are APC-100 APC-200 and APC-300. The Company also has a microbicide product candidate named Savvy (C31G). The Company’s product candidate for the treatment of anaphylaxis is Epinephrine PFS.